HC Wainwright Reaffirms Buy Rating for Oncolytics Biotech (NASDAQ:ONCY)

HC Wainwright reaffirmed their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

Oncolytics Biotech Trading Down 3.0 %

ONCY stock traded down $0.03 during midday trading on Thursday, hitting $0.98. 240,986 shares of the company’s stock were exchanged, compared to its average volume of 328,205. The business has a 50-day simple moving average of $1.09 and a two-hundred day simple moving average of $1.06. The stock has a market capitalization of $75.52 million, a PE ratio of -3.74 and a beta of 1.69. Oncolytics Biotech has a 1-year low of $0.84 and a 1-year high of $1.75.

Institutional Investors Weigh In On Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent SEC filing. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.